Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Status:
Terminated
Trial end date:
2017-05-08
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the progression-free survival, of patients who
receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a
first line treatment followed by everolimus when progression occurs.